Prenetics

📍 Hong Kong, Hong Kong SAR🗓 Founded 2014👥 251 employees💰 Last funded Aug 2017
Biotechnology Research🌐 prenetics.com
Website LinkedIn
Prenetics (NASDAQ:PRE), a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the worlds most comprehensive consumer DNA test. Insighta, our $200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Insighta plans to introduce Presight for lung and liver cancers in 2025, and to expand with Presight One for 10+ cancers in 2027. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics units synergistically enhances our global impact on health, truly embodying our commitment to enhancing life through science.
4
Total investors
1
Early stage
0
Mid stage
3
Late stage
2014
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
Hong Kong SAR
2
Hong Kong
1
Singapore
1
Investor activity2014–2017 · investors recorded per year
201412015120172
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Prenetics?
Prenetics has 4 investors on record on gritt.io, including 1 early-stage backers and 3 late-stage investors.
When did Prenetics last raise funding?
The most recent investment in Prenetics recorded on gritt.io was in August 2017.
When was Prenetics founded?
Prenetics was founded in 2014.
What industry is Prenetics in?
Prenetics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Prenetics based?
Prenetics is headquartered in Hong Kong, Hong Kong SAR.